-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Invitation Letter2021 CSGCT Gene and Cell Therapy Medical Summit will be held in Shanghai ★ Autologous NK cell therapy wants to open up new markets, FDA launches pre-IND meetingYimai Meng broke the news, click on the picture and sign up for the conference in 2021 November 7/eMedClub News/--On November 2, 2021, Shoreline Biosciences, Inc.
(Shoreline), a cutting-edge in the field of iPSC cell therapy, announced that it has received US$140 million in financing
.
The financing was led by Ally Bridge Group, with participation from Eventide Asset Management, BeiGene, Gilead/Kite and others
.
The financing will be used to advance the development of the company's iPSC platform focusing on next-generation NK cell and macrophage therapies to create effective and long-lasting NK cell-specific chimeric antigen receptors (CARs) and switchable CARs -NK cell binding agents and macrophage-specific CARs for the treatment of hematological malignancies, solid tumors and other diseases
.
Kleanthis G.
Xanthopoulos, Co-founder, Chairman and CEO of Shoreline said: "We are very pleased to see Shoreline's tremendous development in the past year, including the next generation of longer-lasting and more effective iPSC-derived NK cells.
, The enhancement of the company’s core technology, the advancement of pre-clinical projects, the partnership with Kite and BeiGene, the creation of intelligent production methods, and the attraction of outstanding talents
.
Through this financing and our corporate partners, Shoreline has now invested more than US$300 million to develop a safe, effective and affordable cellular immunotherapy pipeline for solid tumors and hematological malignancies
.
Frank Yu, Founder, CEO and CIO of Ally Bridge Group, said: "For many years, we have invested in and paid close attention to the iPSC-derived NK cell therapy field.
This field has made encouraging clinical progress.
We believe The unique advantages demonstrated by the Shoreline technology platform
.
As a major investor in a leading cell therapy company from oncology to autoimmune diseases, Ally Bridge Group expects Shoreline to become a leader in this field
.
It’s worth mentioning that Shoreline won the favor of BeiGene and Gilead’s Kite in June this year, and reached two important cooperations
.
On June 9, Shoreline announced that it had reached a cooperation agreement with BeiGene to link Shoreline’s iPSC.
NK cell technology and BeiGene’s preclinical R&D and clinical development capabilities have developed and commercialized a series of NK cell therapy-based product portfolios for the treatment of various malignant tumors
.
According to the terms of the agreement, Shoreline will obtain from BeiGene A cash advance of US$45 million, and is eligible to receive R&D funding, milestone payments and royalties when specific R&D, registration, and commercialization milestones are reached
.
Under the framework of cooperation, BeiGene will lead global clinical development, and Shoreline will be responsible Clinical production
.
On June 17, Shoreline announced the establishment of a strategic partnership pipeline with Kite.
This collaboration will utilize Shoreline’s deep expertise in iPSC differentiation and gene reprogramming, combined with Kite’s extensive experience in cell therapy development, commercialization and manufacturing.
New allogeneic drug candidates for various types of hematomas
.
Under the agreement, Shoreline will receive an advance payment and is eligible for additional payments totaling more than $2.
3 billion and royalties based on certain development and commercial milestones
.
Two cooperation agreements reached within 10 days, totaling billions of dollars, what are the characteristics of Shoreline? Founded in 2020 and headquartered in San Diego, California, Shoreline is committed to promoting intelligently designed off-the-shelf, targeted and standardized iPSC-derived NK and macrophage immunotherapies for treatment Cancer and other serious diseases
.
Currently, the company has established a pipeline of drug candidates for NK cell/macrophage therapy
.
➤ iPSC-derived cell therapy technology platform Shoreline's core cell therapy platform can produce optimized and fully functional immune cell homogenous populations
.
In addition, by cloning selected NK cells derived from iPSCs with new optimized genetic characteristics, this superior NK cells can be expanded to create unlimited homogenous live cell therapy products
.
These cells are then cryopreserved, which can treat a large number of patients within a few hours, reducing time and cost
.
▲Shoreline's iPSC technology platform (picture source: Shoreline official website) ➤ iPSC-derived NK cells NK cells have the natural ability to recognize and kill tumor cells, and at the same time produce cytokines to recruit and activate immune responses
.
They have a fail-safe mechanism to prevent the killing of healthy cells, making NK cells a promising future for cell therapy
.
However, the quality of NK cells derived from cord blood, placenta, and peripheral blood depends on the donor and is therefore variable
.
iPSC-derived NK cells provide a more robust and expandable method for the use of NK cell therapy
.
Shoreline has developed iPSC-derived NK cells, which are genetically engineered to perform optimally in patients
.
Through Shoreline's advanced patented technology, iPSC-derived NK cells are genetically modified, and it has been confirmed in research that NK cells can maintain a longer lifespan and stronger combat effectiveness
.
Gene modification starts from the cell engine, and enhances cell functions by knocking out (KO) specific genes (CISH)
.
▲Engineered iPSC NK cells (picture source: Shoreline official website) In order to further enhance the ability of iPSC-derived NK cells to target and destroy toxic cells, Shoreline has developed a series of targeting and homing chimeric antigen receptors (CARs), Synergize with the new genetic characteristics of iPSC-derived CISH-KO NK cells
.
These tumor-targeted CARs directly bind to specific tumor-associated antigens through antigen-binding fragments (scFv)
.
The protein fragments in the cell act as a signal device to communicate with the cell, and undergo a cascade effect to release cytokines and begin the process of antigen destruction
.
▲iPSC NK cells optimized for CARs (picture source: Shoreline official website) Another tumor targeting device is antibody-dependent cell-mediated cytotoxicity (ADCC), which indirectly attaches to the tumor through monoclonal antibodies injected into the patient's body Express the antigen
.
Once they reach and attach to the tumor, the intracellular signals of these CARs tell NK cells to release cytokines to kill the tumor
.
▲Optimize ADCC (Image source: Shoreline official website) Shoreline's universal CAR platform can redirect iPSC-derived NK cells to different tumor antigens in patients in real time
.
With this technology, there is no need to use traditional methods to chase the evolution of tumors, and multiple antigens can be targeted at one time
.
This universal and scalable application can provide a personalized, ready-to-use treatment plan for each patient
.
▲Universal adapter (picture source: Shoreline official website) ➤ iPSC-derived macrophages Macrophages are innate immune cells that can kill tumor cells and coordinate anti-tumor immune responses
.
However, the role of macrophages in tumor biology is not unilateral, and tumor-associated macrophages are the main components of tumor microenvironment that prevent immune clearance
.
Shoreline's iPSC-derived "M1" macrophages have the best anti-tumor function after genetic modification
.
These cells can regulate the tumor microenvironment, turn them into pro-inflammatory cells, and recruit additional immune effector cells to drive tumor clearance
.
Macrophages can also be used for non-oncology indications, and iPSC-derived "M2" macrophages can be used for regenerative therapy, fibrosis and inflammatory diseases
.
Summary Since the discovery of iPSC technology, stem cell biology and regenerative medicine have made significant progress, and brought a market field of great commercial value
.
After the discovery of iPSC in 2006, it took only 7 years and in 2013 the Japanese government approved the first clinical trial of transplanting iPSC-derived cell products into humans.
.
From 2013 to the present, multiple clinical trials and doctor-led research using human iPSC-derived cell types have been initiated in multiple regions around the world
.
At present, many companies at home and abroad are developing iPSC-derived cell therapies for cancer.
It is hoped that these strategies can smoothly promote the industrialization of cell therapies and benefit more patients
.
Reference materials: 1.
https:// 2.
https ://shorelinebio.
com/
(Shoreline), a cutting-edge in the field of iPSC cell therapy, announced that it has received US$140 million in financing
.
The financing was led by Ally Bridge Group, with participation from Eventide Asset Management, BeiGene, Gilead/Kite and others
.
The financing will be used to advance the development of the company's iPSC platform focusing on next-generation NK cell and macrophage therapies to create effective and long-lasting NK cell-specific chimeric antigen receptors (CARs) and switchable CARs -NK cell binding agents and macrophage-specific CARs for the treatment of hematological malignancies, solid tumors and other diseases
.
Kleanthis G.
Xanthopoulos, Co-founder, Chairman and CEO of Shoreline said: "We are very pleased to see Shoreline's tremendous development in the past year, including the next generation of longer-lasting and more effective iPSC-derived NK cells.
, The enhancement of the company’s core technology, the advancement of pre-clinical projects, the partnership with Kite and BeiGene, the creation of intelligent production methods, and the attraction of outstanding talents
.
Through this financing and our corporate partners, Shoreline has now invested more than US$300 million to develop a safe, effective and affordable cellular immunotherapy pipeline for solid tumors and hematological malignancies
.
Frank Yu, Founder, CEO and CIO of Ally Bridge Group, said: "For many years, we have invested in and paid close attention to the iPSC-derived NK cell therapy field.
This field has made encouraging clinical progress.
We believe The unique advantages demonstrated by the Shoreline technology platform
.
As a major investor in a leading cell therapy company from oncology to autoimmune diseases, Ally Bridge Group expects Shoreline to become a leader in this field
.
It’s worth mentioning that Shoreline won the favor of BeiGene and Gilead’s Kite in June this year, and reached two important cooperations
.
On June 9, Shoreline announced that it had reached a cooperation agreement with BeiGene to link Shoreline’s iPSC.
NK cell technology and BeiGene’s preclinical R&D and clinical development capabilities have developed and commercialized a series of NK cell therapy-based product portfolios for the treatment of various malignant tumors
.
According to the terms of the agreement, Shoreline will obtain from BeiGene A cash advance of US$45 million, and is eligible to receive R&D funding, milestone payments and royalties when specific R&D, registration, and commercialization milestones are reached
.
Under the framework of cooperation, BeiGene will lead global clinical development, and Shoreline will be responsible Clinical production
.
On June 17, Shoreline announced the establishment of a strategic partnership pipeline with Kite.
This collaboration will utilize Shoreline’s deep expertise in iPSC differentiation and gene reprogramming, combined with Kite’s extensive experience in cell therapy development, commercialization and manufacturing.
New allogeneic drug candidates for various types of hematomas
.
Under the agreement, Shoreline will receive an advance payment and is eligible for additional payments totaling more than $2.
3 billion and royalties based on certain development and commercial milestones
.
Two cooperation agreements reached within 10 days, totaling billions of dollars, what are the characteristics of Shoreline? Founded in 2020 and headquartered in San Diego, California, Shoreline is committed to promoting intelligently designed off-the-shelf, targeted and standardized iPSC-derived NK and macrophage immunotherapies for treatment Cancer and other serious diseases
.
Currently, the company has established a pipeline of drug candidates for NK cell/macrophage therapy
.
➤ iPSC-derived cell therapy technology platform Shoreline's core cell therapy platform can produce optimized and fully functional immune cell homogenous populations
.
In addition, by cloning selected NK cells derived from iPSCs with new optimized genetic characteristics, this superior NK cells can be expanded to create unlimited homogenous live cell therapy products
.
These cells are then cryopreserved, which can treat a large number of patients within a few hours, reducing time and cost
.
▲Shoreline's iPSC technology platform (picture source: Shoreline official website) ➤ iPSC-derived NK cells NK cells have the natural ability to recognize and kill tumor cells, and at the same time produce cytokines to recruit and activate immune responses
.
They have a fail-safe mechanism to prevent the killing of healthy cells, making NK cells a promising future for cell therapy
.
However, the quality of NK cells derived from cord blood, placenta, and peripheral blood depends on the donor and is therefore variable
.
iPSC-derived NK cells provide a more robust and expandable method for the use of NK cell therapy
.
Shoreline has developed iPSC-derived NK cells, which are genetically engineered to perform optimally in patients
.
Through Shoreline's advanced patented technology, iPSC-derived NK cells are genetically modified, and it has been confirmed in research that NK cells can maintain a longer lifespan and stronger combat effectiveness
.
Gene modification starts from the cell engine, and enhances cell functions by knocking out (KO) specific genes (CISH)
.
▲Engineered iPSC NK cells (picture source: Shoreline official website) In order to further enhance the ability of iPSC-derived NK cells to target and destroy toxic cells, Shoreline has developed a series of targeting and homing chimeric antigen receptors (CARs), Synergize with the new genetic characteristics of iPSC-derived CISH-KO NK cells
.
These tumor-targeted CARs directly bind to specific tumor-associated antigens through antigen-binding fragments (scFv)
.
The protein fragments in the cell act as a signal device to communicate with the cell, and undergo a cascade effect to release cytokines and begin the process of antigen destruction
.
▲iPSC NK cells optimized for CARs (picture source: Shoreline official website) Another tumor targeting device is antibody-dependent cell-mediated cytotoxicity (ADCC), which indirectly attaches to the tumor through monoclonal antibodies injected into the patient's body Express the antigen
.
Once they reach and attach to the tumor, the intracellular signals of these CARs tell NK cells to release cytokines to kill the tumor
.
▲Optimize ADCC (Image source: Shoreline official website) Shoreline's universal CAR platform can redirect iPSC-derived NK cells to different tumor antigens in patients in real time
.
With this technology, there is no need to use traditional methods to chase the evolution of tumors, and multiple antigens can be targeted at one time
.
This universal and scalable application can provide a personalized, ready-to-use treatment plan for each patient
.
▲Universal adapter (picture source: Shoreline official website) ➤ iPSC-derived macrophages Macrophages are innate immune cells that can kill tumor cells and coordinate anti-tumor immune responses
.
However, the role of macrophages in tumor biology is not unilateral, and tumor-associated macrophages are the main components of tumor microenvironment that prevent immune clearance
.
Shoreline's iPSC-derived "M1" macrophages have the best anti-tumor function after genetic modification
.
These cells can regulate the tumor microenvironment, turn them into pro-inflammatory cells, and recruit additional immune effector cells to drive tumor clearance
.
Macrophages can also be used for non-oncology indications, and iPSC-derived "M2" macrophages can be used for regenerative therapy, fibrosis and inflammatory diseases
.
Summary Since the discovery of iPSC technology, stem cell biology and regenerative medicine have made significant progress, and brought a market field of great commercial value
.
After the discovery of iPSC in 2006, it took only 7 years and in 2013 the Japanese government approved the first clinical trial of transplanting iPSC-derived cell products into humans.
.
From 2013 to the present, multiple clinical trials and doctor-led research using human iPSC-derived cell types have been initiated in multiple regions around the world
.
At present, many companies at home and abroad are developing iPSC-derived cell therapies for cancer.
It is hoped that these strategies can smoothly promote the industrialization of cell therapies and benefit more patients
.
Reference materials: 1.
https:// 2.
https ://shorelinebio.
com/
